Filtered By:
Infectious Disease: Coronavirus
Vaccination: Vaccines

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 194 results found since Jan 2013.

Mechanistic Episodes on SARS-CoV-2-Mediated Neurological Manifestations and Their Possible Therapeutic Interventions
J Environ Pathol Toxicol Oncol. 2022;41(1):85-98. doi: 10.1615/JEnvironPatholToxicolOncol.2021040128.ABSTRACTRecently, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been critically recognized and spread rapidly on this planet. Considerable recognition of SARS-CoV-2 has been known with a range of viruses that are more capable to cause diseases in avian and mammals including humans. The virus was found as a main culprit for major defects in respiratory system and thereby caused severe acute respiratory syndrome disease. This has led to depict the mortality in human population. Nevertheless...
Source: Journal of Environmental Pathology, Toxicology and Oncology - April 4, 2022 Category: Environmental Health Authors: Sobia Nida Hemalatha Srinivisan Ashok Kumar Pandurangan Mohammad Waseem Source Type: research

Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties
In conclusion, COVID-19 and related vaccines are linked with the development of HVS, mainly in patients with previous COVID-19 and underlying metabolic derangements. The possible mechanism of HVS in COVID-19 and related vaccines is increasing levels of fibrinogen and immunoglobulins. However, dehy dration, oxidative stress, and inflammatory reactions are regarded as additional contributing factors in the pathogenesis of HVS in COVID-19. However, this critical review cannot determine the final causal relationship between COVID-19 and related vaccines and the development of HVS. Prospective and retrospective studies are warranted in this field.
Source: Clinical and Experimental Medicine - May 24, 2022 Category: Research Source Type: research

Isolated and Combined Unilateral Central Retinal Artery and Vein Occlusions After Vaccination. A Review of the Literature
Retinal artery occlusion (RAO), especially central RAO, is a sight-threatening and potentially blinding ophthalmic emergency. Recent publications reported its association with coronavirus disease 2019 (COVID-19) mRNA vaccines. Although rare, vaccines have been linked to ophthalmic complications, and it is of interest to examine the current literature on vaccine-related RAO.
Source: Journal of Stroke and Cerebrovascular Diseases - May 12, 2022 Category: Neurology Authors: Clarice, Kai-ying Su, Sunny, Chi Lik Au Tags: Short Communication Source Type: research

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
In conclusion, this review has concisely summarized the current rare adverse events related and unrelated to BNT162b2, arguably for the first time in sufficient depth, to better communicate vaccine safety to the public.PMID:35891231 | DOI:10.3390/vaccines10071067
Source: Herpes - July 27, 2022 Category: Infectious Diseases Authors: Shin-Jie Yong Alice Halim Michael Halim Abbas Al Mutair Saad Alhumaid Jehad Al-Sihati Hawra Albayat Mohammed Alsaeed Mohammed Garout Reyouf Al Azmi Noor Aldakheel Abeer N Alshukairi Hani A Al Ali Adel A Almoumen Ali A Rabaan Source Type: research

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Is a high chest CT severity score a risk factor for an increased incidence of long-term neuroimaging findings after COVID-19?
From the outbreak of the Coronavirus disease 2019 (COVID-19) pandemic on 17 November 2019 in Wuhan to 2 November 2022, the total number of cases was reported as 617,879,854 and the total number of deaths was reported as 6,546,448 worldwide 1. In Turkey, the first case was reported on March 11, 2020. Until November 2, 2022, the total number of cases was 16,873,793 and the total number of deaths was 101,139 1. Today, there is a significant decrease in the number of cases and deaths as a result of vaccination and mutations in the virus.
Source: Journal of Stroke and Cerebrovascular Diseases - November 29, 2022 Category: Neurology Authors: Ahmet-Turan Kaya, Burcu Akman Source Type: research

Neurological Complications and Consequences of the Novel Coronavirus COVID-19 Infection in Elderly and Senile Patients (Literature Review)
AbstractBased on available publications, the article systematizes information about some forms of lesions of the central nervous system (CNS), their pathogenesis and clinical manifestations in the case of COVID-19. The risk factors, mechanisms of development, diagnostic approach, and the age characteristics of patients with neurological complications of COVID-19 are discussed. The specific mechanisms of the neuroinvasiveness and neurovirulence of the SARS-CoV-2 virus, regardless of the age of patients and the presence of risk factors, lead to systemic damage to the endothelium of small-caliber vessels, generalized thrombov...
Source: Advances in Gerontology - December 1, 2022 Category: Geriatrics Source Type: research

The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are. That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature
Vaccines (Basel). 2023 Feb 13;11(2):425. doi: 10.3390/vaccines11020425.ABSTRACTCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in 2019 and became a pandemic in 2020. Since then, vaccines have been approved to prevent severe illness. However, vaccines are associated with the risk of neurological complications ranging from mild to severe. Severe complications such as vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with acute ischaemic stroke have been reported as rare complications post-COVID-19 vaccination. During the pandemic era, V...
Source: Herpes - February 28, 2023 Category: Infectious Diseases Authors: Wei-Ping Chen Ming-Hua Chen Shih-Ta Shang Yung-Hsi Kao Kuo-An Wu Wen-Fang Chiang Jenq-Shyong Chan Hann-Yeh Shyu Po-Jen Hsiao Source Type: research